Roche presents promising results for new wet AMD product

26 July 2018
2019_biotech_test_vial_discovery_big

Roche (ROG: SIX) group member Genentech has revealed positive top-line results from the Phase II LADDER study of its investigational Port Delivery System with ranibizumab (PDS) in people with wet age-related macular degeneration (AMD).

The PDS system is a small, refillable eye implant designed to allow people with wet AMD to go several months without needing to visit the doctor.

Most PDS patients enrolled in the LADDER trial went six months or longer between implant of the device and the first required refill.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology